Demand for cosmetic treatments soars post-lockdown, doubling from last year
Cosmetic treatment company Uvence has defied the odds by spring-boarding through the Coronavirus era with booming success. As the cosmetic treatments industry undergoes huge growth, with top practices such as the Cadogan Clinic seeing a 100% increase in bookings from last year, Uvence is riding the wave to bring forth their innovation in aesthetics.
As the UK’s first 100% natural cosmetic procedure, Uvence has harnessed the widespread demand for non-surgical treatments as a way to successfully launch into an industry which has grown by over 55% in under a decade.
With the regulations surrounding masks compelling us into a world which prioritises the aesthetics of the eyes and forehead, Uvence offers a fully-regulated, on-demand tool for skin rejuvenation.
Pioneered by leading cosmetic surgeon Dr. Olivier Amar, the procedure is the only one of its kind fully regulated by the Human Tissue Authority (HTA). Uvence is rolling out in clinics across Britain to disrupt what is a rapidly growing £3bn industry in the UK, with 90% of which being made up of non-surgical treatments.
The company, which launched its treatment in London last month, is backed by a suite of private investors hailing from the UK, France, Monaco, Greece, the Middle East and Canada. Following their early success and growing popularity, Uvence is currently preparing for a raise later this month.
The Uvence treatment
Uvence creates its personalised products from a patient’s own fat cells, which are extracted by an initial micro or mini liposuction. Upon extraction, the fat cells are purified to create Uvence’s patented “Super Enriched Tissue”, before being re-injected to immediately rejuvenate and dramatically improve the smoothness and elasticity of the skin.
The treatment can be carried out proactively, or can be used as a reactive solution to treat ‘filler face’ or poorly administered Botox treatments. Uvence can also preserve 10 injectable vials of the Super Enriched Tissue for up to 5 years, following the initial extraction, thereby providing Uvence’s patients with a long-term, natural solution to maintain a rejuvenated, youthful aesthetic.
Dr. Olivier Amar is one of Europe’s leading aesthetic consultants, with over 15 years of experience in cosmetic, plastic and reconstructive surgery. Now, Olivier comments on the development of the revolutionary Uvence treatment.
“The Uvence offering allows access to regenerative and personalised treatments and is the biggest advancement in the field for nearly 15 years. This exciting and innovative approach is exactly what my clients are demanding now that they are required to wear masks, and only have their eyes and forehead on show for the majority of their day.
This really is the future of cosmetic skin treatments, and I am extremely proud to be part of the next step in standardisation and quality for the cosmetic treatment industry.”
Reece Tomlinson, Profit500 business leader and CEO of Uvence:
“As we enter a post-Covid world, the aesthetic medical space is in the midst of a dramatic change. The demand for mask-friendly cosmetic treatments is seeing huge growth, and Uvence provides just that.
We viewed the utilisation of the body’s own capacity to repair itself as being a prime opportunity to provide the next generation of treatment options for patients. The cosmetic surgery market is expected to be worth $43.9bn by 2025, and we believe that Uvence’s process, technology, and storage facilities offer a genuinely game-changing alternative to invasive cosmetic treatments.”
Dr. Maryam Zamani, leading oculoplastic surgeon, discusses why she is offering Uvence treatments:
“I think this is a perfect addition to the arsenal of treatments I provide. Uvence is an innovative way to harvest small amounts of fat in a short procedure to then prepare into super enriched tissue to help improve quality of the skin. It can be used in combination with injectables, energy based treatments and surgery to bolster collagen production and a more youthful preservation.